Concepts (216)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Migraine Disorders | 9 | 2021 | 530 | 1.76 | Why? |
| Botulinum Toxins, Type A | 3 | 2020 | 134 | 1.59 | Why? |
| Headache | 8 | 2020 | 2257 | 1.18 | Why? |
| Hypoglossal Nerve Diseases | 1 | 2018 | 17 | 0.76 | Why? |
| Charles Bonnet Syndrome | 1 | 2016 | 1 | 0.70 | Why? |
| Vertigo | 1 | 2018 | 141 | 0.67 | Why? |
| Taste Disorders | 4 | 2021 | 1720 | 0.66 | Why? |
| Intracranial Hypotension | 1 | 2014 | 4 | 0.60 | Why? |
| Cerebrospinal Fluid Pressure | 1 | 2014 | 17 | 0.60 | Why? |
| Cerebral Veins | 1 | 2014 | 81 | 0.53 | Why? |
| Vision Disorders | 1 | 2017 | 260 | 0.51 | Why? |
| Hemifacial Spasm | 1 | 2012 | 5 | 0.50 | Why? |
| Facial Nerve Diseases | 1 | 2012 | 10 | 0.50 | Why? |
| Nimodipine | 1 | 2012 | 9 | 0.49 | Why? |
| Glaucoma | 1 | 2016 | 225 | 0.49 | Why? |
| Nerve Block | 2 | 2020 | 183 | 0.48 | Why? |
| SUNCT Syndrome | 1 | 2010 | 2 | 0.43 | Why? |
| Spinal Nerves | 1 | 2010 | 18 | 0.42 | Why? |
| Bupivacaine | 1 | 2010 | 24 | 0.42 | Why? |
| Intracranial Thrombosis | 1 | 2014 | 339 | 0.40 | Why? |
| Headache Disorders, Secondary | 2 | 2020 | 56 | 0.40 | Why? |
| Calcium Channel Blockers | 1 | 2012 | 367 | 0.36 | Why? |
| Brain Diseases | 1 | 2020 | 1463 | 0.36 | Why? |
| Posterior Leukoencephalopathy Syndrome | 1 | 2012 | 213 | 0.36 | Why? |
| Trigeminal Neuralgia | 2 | 2018 | 19 | 0.36 | Why? |
| Facial Pain | 2 | 2018 | 43 | 0.28 | Why? |
| Guillain-Barre Syndrome | 3 | 2021 | 1495 | 0.26 | Why? |
| Biological Products | 1 | 2018 | 2331 | 0.25 | Why? |
| Intubation, Intratracheal | 1 | 2018 | 3962 | 0.24 | Why? |
| Tension-Type Headache | 1 | 2020 | 28 | 0.21 | Why? |
| Sensation Disorders | 1 | 2020 | 103 | 0.20 | Why? |
| Oculomotor Nerve Diseases | 1 | 2020 | 44 | 0.20 | Why? |
| Multiple Sclerosis | 3 | 2020 | 2600 | 0.20 | Why? |
| Alemtuzumab | 1 | 2020 | 121 | 0.20 | Why? |
| Neuralgia | 1 | 2020 | 99 | 0.19 | Why? |
| Visual Cortex | 1 | 2018 | 12 | 0.19 | Why? |
| Confusion | 1 | 2020 | 256 | 0.19 | Why? |
| Blindness, Cortical | 1 | 2018 | 15 | 0.19 | Why? |
| Fingolimod Hydrochloride | 1 | 2020 | 217 | 0.18 | Why? |
| Prescriptions | 1 | 2020 | 258 | 0.18 | Why? |
| Tomography, Optical Coherence | 3 | 2021 | 1008 | 0.18 | Why? |
| Spain | 10 | 2021 | 15545 | 0.18 | Why? |
| Meningoencephalitis | 1 | 2021 | 208 | 0.18 | Why? |
| Prion Proteins | 1 | 2017 | 12 | 0.18 | Why? |
| Portraits as Topic | 1 | 2017 | 19 | 0.17 | Why? |
| Olfaction Disorders | 3 | 2020 | 3704 | 0.17 | Why? |
| Amblyopia | 1 | 2017 | 15 | 0.17 | Why? |
| Arteriovenous Fistula | 1 | 2017 | 23 | 0.17 | Why? |
| Creutzfeldt-Jakob Syndrome | 1 | 2017 | 35 | 0.17 | Why? |
| Carboplatin | 1 | 2017 | 76 | 0.17 | Why? |
| Papilledema | 1 | 2017 | 42 | 0.17 | Why? |
| Cranial Nerve Diseases | 1 | 2018 | 148 | 0.16 | Why? |
| Paintings | 1 | 2017 | 35 | 0.16 | Why? |
| Laryngoscopes | 1 | 2018 | 121 | 0.16 | Why? |
| Amyloid | 1 | 2017 | 156 | 0.16 | Why? |
| Medicine in the Arts | 1 | 2017 | 58 | 0.15 | Why? |
| Spinal Cord Diseases | 1 | 2017 | 141 | 0.15 | Why? |
| Epilepsy, Complex Partial | 1 | 2014 | 1 | 0.15 | Why? |
| Magnetic Resonance Imaging | 4 | 2018 | 6551 | 0.15 | Why? |
| Arnold-Chiari Malformation | 1 | 2014 | 7 | 0.15 | Why? |
| Pseudotumor Cerebri | 1 | 2014 | 18 | 0.14 | Why? |
| Central Nervous System | 1 | 2020 | 701 | 0.14 | Why? |
| Humans | 45 | 2021 | 930598 | 0.13 | Why? |
| Multiple Sclerosis, Relapsing-Remitting | 1 | 2020 | 529 | 0.13 | Why? |
| Ophthalmologists | 1 | 2020 | 401 | 0.13 | Why? |
| Dyslipidemias | 1 | 2020 | 791 | 0.13 | Why? |
| Quality Indicators, Health Care | 1 | 2019 | 580 | 0.13 | Why? |
| Furin | 1 | 2020 | 1054 | 0.12 | Why? |
| Neurodegenerative Diseases | 1 | 2018 | 469 | 0.12 | Why? |
| Immunosuppressive Agents | 2 | 2020 | 6331 | 0.11 | Why? |
| Hospital Units | 1 | 2019 | 1017 | 0.11 | Why? |
| Positron-Emission Tomography | 1 | 2017 | 802 | 0.11 | Why? |
| Nervous System Diseases | 2 | 2020 | 4092 | 0.11 | Why? |
| Occipital Bone | 1 | 2010 | 2 | 0.11 | Why? |
| Cyclohexanecarboxylic Acids | 1 | 2010 | 15 | 0.11 | Why? |
| Amines | 1 | 2010 | 67 | 0.10 | Why? |
| gamma-Aminobutyric Acid | 1 | 2010 | 52 | 0.10 | Why? |
| Functional Laterality | 1 | 2010 | 57 | 0.10 | Why? |
| Electromyography | 1 | 2012 | 278 | 0.10 | Why? |
| Health Personnel | 1 | 2020 | 29646 | 0.10 | Why? |
| Multivariate Analysis | 1 | 2021 | 5440 | 0.10 | Why? |
| Fluorodeoxyglucose F18 | 1 | 2017 | 1153 | 0.10 | Why? |
| Female | 20 | 2021 | 380317 | 0.10 | Why? |
| Gastrointestinal Diseases | 2 | 2020 | 2580 | 0.09 | Why? |
| Patient Safety | 2 | 2020 | 4885 | 0.09 | Why? |
| Triazines | 1 | 2010 | 246 | 0.09 | Why? |
| Male | 16 | 2021 | 367725 | 0.08 | Why? |
| Brain | 2 | 2017 | 5133 | 0.08 | Why? |
| Sleep Wake Disorders | 1 | 2018 | 1463 | 0.08 | Why? |
| Anesthetics, Local | 1 | 2010 | 205 | 0.08 | Why? |
| Cough | 1 | 2020 | 4891 | 0.08 | Why? |
| Epilepsy | 1 | 2018 | 1401 | 0.08 | Why? |
| Parkinson Disease | 1 | 2018 | 1414 | 0.08 | Why? |
| Eye Diseases | 1 | 2017 | 1150 | 0.08 | Why? |
| Hypertension | 2 | 2020 | 8895 | 0.07 | Why? |
| Occupational Diseases | 1 | 2020 | 2787 | 0.07 | Why? |
| Dementia | 1 | 2018 | 1861 | 0.07 | Why? |
| Anticonvulsants | 1 | 2010 | 634 | 0.07 | Why? |
| Serine Endopeptidases | 1 | 2020 | 4606 | 0.07 | Why? |
| Inpatients | 1 | 2020 | 5161 | 0.07 | Why? |
| Middle Aged | 12 | 2021 | 270681 | 0.07 | Why? |
| Pandemics | 9 | 2020 | 389249 | 0.07 | Why? |
| C-Reactive Protein | 1 | 2020 | 7972 | 0.07 | Why? |
| Pharmaceutical Preparations | 1 | 2018 | 1897 | 0.07 | Why? |
| Occupational Health | 1 | 2020 | 3965 | 0.07 | Why? |
| Receptors, Virus | 1 | 2020 | 5659 | 0.06 | Why? |
| Fever | 1 | 2020 | 7795 | 0.06 | Why? |
| Brain Ischemia | 1 | 2018 | 2813 | 0.06 | Why? |
| Length of Stay | 1 | 2020 | 11042 | 0.06 | Why? |
| Recurrence | 1 | 2012 | 3675 | 0.06 | Why? |
| Child | 4 | 2021 | 70012 | 0.06 | Why? |
| Aged | 8 | 2021 | 215776 | 0.06 | Why? |
| Adult | 9 | 2021 | 244371 | 0.06 | Why? |
| Diabetes Mellitus | 2 | 2020 | 8207 | 0.05 | Why? |
| Nerve Fibers | 1 | 2021 | 73 | 0.05 | Why? |
| Cross-Sectional Studies | 4 | 2021 | 53120 | 0.05 | Why? |
| Registries | 1 | 2021 | 12327 | 0.05 | Why? |
| Surveys and Questionnaires | 4 | 2020 | 43792 | 0.05 | Why? |
| Retinal Ganglion Cells | 1 | 2021 | 80 | 0.05 | Why? |
| Optic Nerve | 1 | 2021 | 123 | 0.05 | Why? |
| Cohort Studies | 2 | 2021 | 36005 | 0.05 | Why? |
| Pneumonia, Viral | 5 | 2020 | 243684 | 0.05 | Why? |
| Coronavirus Infections | 5 | 2020 | 253789 | 0.05 | Why? |
| Hospital Mortality | 2 | 2021 | 22087 | 0.05 | Why? |
| Agnosia | 1 | 2018 | 12 | 0.05 | Why? |
| Cranial Nerves | 1 | 2018 | 37 | 0.05 | Why? |
| Anticoagulants | 1 | 2020 | 9563 | 0.05 | Why? |
| Comorbidity | 2 | 2020 | 34796 | 0.05 | Why? |
| Breast Neoplasms | 1 | 2017 | 3633 | 0.05 | Why? |
| Hypesthesia | 1 | 2018 | 60 | 0.05 | Why? |
| Diagnosis, Differential | 3 | 2018 | 7220 | 0.05 | Why? |
| Mydriasis | 1 | 2017 | 1 | 0.04 | Why? |
| Enophthalmos | 1 | 2017 | 2 | 0.04 | Why? |
| Whole Exome Sequencing | 1 | 2020 | 437 | 0.04 | Why? |
| Prevalence | 1 | 2020 | 25773 | 0.04 | Why? |
| Orbital Fractures | 1 | 2017 | 15 | 0.04 | Why? |
| Retinal Vessels | 1 | 2021 | 255 | 0.04 | Why? |
| Paresis | 1 | 2018 | 77 | 0.04 | Why? |
| Hypoxia-Ischemia, Brain | 1 | 2018 | 86 | 0.04 | Why? |
| Neurology | 2 | 2020 | 1613 | 0.04 | Why? |
| Reflex, Pupillary | 1 | 2017 | 33 | 0.04 | Why? |
| Blepharoptosis | 1 | 2017 | 31 | 0.04 | Why? |
| Fluorescein Angiography | 1 | 2021 | 426 | 0.04 | Why? |
| Risk Factors | 3 | 2021 | 71621 | 0.04 | Why? |
| History, 16th Century | 1 | 2017 | 104 | 0.04 | Why? |
| Prognosis | 1 | 2021 | 32490 | 0.04 | Why? |
| Neuropathology | 1 | 2017 | 95 | 0.04 | Why? |
| Aniline Compounds | 1 | 2017 | 120 | 0.04 | Why? |
| Vision, Low | 1 | 2017 | 53 | 0.04 | Why? |
| Hydroxychloroquine | 1 | 2020 | 12447 | 0.04 | Why? |
| Patient Satisfaction | 2 | 2019 | 2517 | 0.04 | Why? |
| Stilbenes | 1 | 2017 | 113 | 0.04 | Why? |
| Symptom Assessment | 2 | 2020 | 4967 | 0.04 | Why? |
| Personal Protective Equipment | 1 | 2020 | 15978 | 0.04 | Why? |
| Influenza, Human | 1 | 2020 | 10779 | 0.04 | Why? |
| Outpatient Clinics, Hospital | 1 | 2020 | 523 | 0.04 | Why? |
| Incidence | 3 | 2021 | 25622 | 0.03 | Why? |
| Intensive Care Units | 1 | 2020 | 29594 | 0.03 | Why? |
| Hospital Departments | 1 | 2020 | 831 | 0.03 | Why? |
| Polymorphism, Genetic | 1 | 2020 | 1074 | 0.03 | Why? |
| Pain | 1 | 2020 | 1084 | 0.03 | Why? |
| Social Networking | 1 | 2019 | 737 | 0.03 | Why? |
| Radiopharmaceuticals | 1 | 2017 | 763 | 0.03 | Why? |
| Case-Control Studies | 2 | 2020 | 17671 | 0.03 | Why? |
| Congresses as Topic | 1 | 2021 | 1347 | 0.03 | Why? |
| Health Priorities | 1 | 2020 | 959 | 0.03 | Why? |
| Disease Management | 2 | 2020 | 6841 | 0.03 | Why? |
| Exanthema | 1 | 2020 | 1097 | 0.03 | Why? |
| Gene Expression | 1 | 2020 | 3332 | 0.02 | Why? |
| Treatment Outcome | 2 | 2020 | 51732 | 0.02 | Why? |
| Betacoronavirus | 4 | 2020 | 204454 | 0.02 | Why? |
| Patient Education as Topic | 1 | 2019 | 1476 | 0.02 | Why? |
| Home Care Services | 1 | 2020 | 1351 | 0.02 | Why? |
| Immunoglobulins, Intravenous | 1 | 2020 | 2705 | 0.02 | Why? |
| Aged, 80 and over | 3 | 2017 | 88759 | 0.02 | Why? |
| Self Report | 1 | 2020 | 3802 | 0.02 | Why? |
| Heart Arrest | 1 | 2018 | 1239 | 0.02 | Why? |
| Critical Care | 2 | 2021 | 14081 | 0.02 | Why? |
| Quality of Health Care | 1 | 2019 | 1948 | 0.02 | Why? |
| Time Factors | 1 | 2010 | 31397 | 0.02 | Why? |
| Patient Isolation | 1 | 2020 | 3182 | 0.02 | Why? |
| Decision Making | 1 | 2020 | 3132 | 0.02 | Why? |
| Genetic Predisposition to Disease | 1 | 2020 | 4027 | 0.02 | Why? |
| Evidence-Based Medicine | 1 | 2018 | 3228 | 0.02 | Why? |
| Hospitalization | 3 | 2021 | 54280 | 0.02 | Why? |
| Polymerase Chain Reaction | 1 | 2020 | 6740 | 0.02 | Why? |
| Fibrin Fibrinogen Degradation Products | 1 | 2021 | 5993 | 0.02 | Why? |
| Guidelines as Topic | 1 | 2017 | 2844 | 0.02 | Why? |
| Immunologic Factors | 1 | 2020 | 4206 | 0.02 | Why? |
| Europe | 1 | 2021 | 12702 | 0.02 | Why? |
| Protein Binding | 1 | 2020 | 11430 | 0.02 | Why? |
| Emergency Medical Services | 1 | 2020 | 3557 | 0.02 | Why? |
| Referral and Consultation | 1 | 2019 | 4816 | 0.02 | Why? |
| Antibodies, Monoclonal | 1 | 2021 | 8041 | 0.01 | Why? |
| Disease Models, Animal | 1 | 2020 | 10998 | 0.01 | Why? |
| Virus Internalization | 1 | 2020 | 7921 | 0.01 | Why? |
| Mice | 1 | 2020 | 21357 | 0.01 | Why? |
| Host-Pathogen Interactions | 1 | 2020 | 11041 | 0.01 | Why? |
| Age Factors | 1 | 2020 | 21039 | 0.01 | Why? |
| Antibodies, Monoclonal, Humanized | 1 | 2020 | 9335 | 0.01 | Why? |
| Clinical Trials as Topic | 1 | 2017 | 7330 | 0.01 | Why? |
| Inflammation | 1 | 2020 | 13255 | 0.01 | Why? |
| Retrospective Studies | 2 | 2021 | 105322 | 0.01 | Why? |
| Biomarkers | 1 | 2020 | 23361 | 0.01 | Why? |
| Practice Guidelines as Topic | 1 | 2021 | 15421 | 0.01 | Why? |
| Emergency Service, Hospital | 1 | 2021 | 14232 | 0.01 | Why? |
| Risk Assessment | 1 | 2020 | 25439 | 0.01 | Why? |
| Young Adult | 2 | 2018 | 93724 | 0.01 | Why? |
| Cardiovascular Diseases | 1 | 2020 | 11497 | 0.01 | Why? |
| Prospective Studies | 1 | 2019 | 43301 | 0.01 | Why? |
| RNA, Viral | 1 | 2020 | 32276 | 0.01 | Why? |
| Lung | 1 | 2021 | 31049 | 0.01 | Why? |
| Severity of Illness Index | 1 | 2020 | 48226 | 0.01 | Why? |
| Animals | 1 | 2020 | 78931 | 0.01 | Why? |
| Spike Glycoprotein, Coronavirus | 1 | 2020 | 37182 | 0.01 | Why? |
| Telemedicine | 1 | 2020 | 25032 | 0.01 | Why? |